A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

June 4, 2025

Study Completion Date

June 4, 2025

Conditions
Hypercholesterolemia
Interventions
DRUG

Bempedoic acid

Once daily oral dosing with oral tablets.

Trial Locations (24)

2100

Rigshospitalet, Copenhagen

8208

Corporacio Sanitaria Parc Tauli - Hospital de Sabadell, Barcelona

8950

Hospital Sant Joan de Deu, Barcelona

11407

Hospital Universitario de Jerez de la Frontera, Cadiz

14004

Hospital Universitario Reina Sofia, Córdoba

15001

Hospital Abente y Lago, A Coruña

17601

Cardiology Care for Children, Lancaster

27157

Wake Forest University Health Sciences, Winston-Salem

28034

Hospital Universitario Ramon y Cajal, Madrid

33434

Excel Medical Clinical Trials, LLC, Boca Raton

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

63110

Washington University School of Medicine, Division of Endocrinology, Metabolism and Lipid Research, St Louis

84113

University of Utah and Primary Children's Hospital, Salt Lake City

90048

Cedars-Sinai Medical Center, Los Angeles

91790

Providere Research Inc, West Covina

T6G 2B7

University of Alberta Hospital - Stollery Children's Hospital, Edmonton

L8N 3Z5

McMaster University Medical Center, Hamilton

G7H 5H6

Ecogene-21, Chicoutimi

Unknown

Viborg Regional Hospital, Viborg

Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet, Frankfurt am Main

Kinder- und Jugendkrankenhaus AUF DER BULT, Hanover

Hospital Universitario 12 de Octubre, Madrid

1105 AZ

Amsterdam UMC - Locatie AMC, Amsterdam

3015 G

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
lead

Esperion Therapeutics, Inc.

INDUSTRY